Hollencrest Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Hollencrest Capital Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70	Closed	-$11.6K	–	1180
2025 Q3	$11.6K	Hold	70	–	–	﹤0.01%	776
2025 Q2	$10.7K	Hold	70	–	–	﹤0.01%	758
2025 Q1	$11K	Hold	70	–	–	﹤0.01%	748
2024 Q4	$11K	Hold	70	–	–	﹤0.01%	774
2024 Q3	$12.4K	Sell	70 -60	-46%	-$10.6K	﹤0.01%	727
2024 Q2	$21.9K	Buy	130 +60	+86%	+$9.81K	﹤0.01%	650
2024 Q1	$11.6K	Hold	70	–	–	﹤0.01%	696
2023 Q4	$11.6K	Hold	70	–	–	﹤0.01%	708
2023 Q3	$10.9K	Hold	70	–	–	﹤0.01%	716
2023 Q2	$10.9K	Hold	70	–	–	﹤0.01%	743
2023 Q1	$11.3K	Hold	70	–	–	﹤0.01%	729
2022 Q4	$11.2K	Buy	+70	New	+$11.1K	﹤0.01%	714

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

Hollencrest Capital Management's BBH Position: Q4 2025 in Review

Hollencrest Capital Management sold out of VanEck Biotech ETF (BBH) in Q4 2025, closing a stake of 70 shares — an estimated $11.6K sold.

Hollencrest Capital Management first reported a position in BBH in Q4 2022 and held it in 12 quarters. The position peaked at $21.9K in Q2 2024. 111 funds tracked by Wall St. Rank hold BBH as of Q4 2025.

Hollencrest Capital Management reported no remaining VanEck Biotech ETF position as of Q4 2025 after selling out during the quarter.
Hollencrest Capital Management sold 70 VanEck Biotech ETF shares in Q4 2025, an estimated $11.6K.
Hollencrest Capital Management first reported a position in VanEck Biotech ETF in Q4 2022 and held it in 12 quarters.
Hollencrest Capital Management's VanEck Biotech ETF position peaked at $21.9K in Q2 2024.
111 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2025.

Based on Hollencrest Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.